Further supporting the differential reliance on BCR signaling are the observations that differential antitumor activity against UM- and M-CLL appears to be commonly shared among several other BCR-directed inhibitors besides ibrutinib. The gene discussed is BCR; the disease is B-cell chronic lymphocytic leukemia.